Although tumor mutational burden, PD-L1 expression and CD8+ T cell infiltration at baseline appear to enrich for response to ICIs [8,9,10,11,12], these biomarkers are not accurate enough to be used as stand-alone biomarkers. The gene discussed is CD8A; the disease is neoplasm.